�MDRNA, Inc. (Nasdaq: MRNA) announced positive in vivo efficacy information on its proprietary RNAi-based therapeutic for the treatment of multiple strains of influenza A virus in animal models. The in vivo data were presented by Shaguna Seth, Ph.D., Associate Director at MDRNA, Inc., at the XIV International Congress of Virology in Istanbul, Turkey.
"Our Influenza Program is a superb example of the convergence of both our novel RNAi technologies and proprietary do drugs delivery capabilities," stated J. Michael French, Chief Executive Officer at MDRNA. "In order to accelerate evolution of this important pb candidate, capitalise on the significant research effort conducted by our team and fully earn its commercial potential as a therapeutic against a pandemic grippe outbreak; we are seeking a strategical partnership with a company focused in the biological defence or infectious disease region."
The information reported at the group discussion indicate that MDRNA's Dicer substrate siRNAs are highly active against multiple strains of grippe A virus including seasonal worker H3N2 and highly infective H5N1 strains. The star Dicer siRNA also evoked high suppression activity against Tamiflu-resistant strains of influenza virus. Treatment with MDRNA's lead nominee before and after infection resulted in a hundred to 1000-fold (99%) reduction in viral titers, therefore demonstrating their potential use as a therapeutic as well as a contraceptive. Formulated Dicer substrates dosed intranasally showed significant simplification in viral replication; leading to glower viral titers, decreased clinical signs, and increased survival in infected mice and ferret models of flu. MDRNA's proprietorship delivery formulations provided greater therapeutic benefit at lower siRNA dosage levels, as compared to siRNA dosed without formulation.
"There is a important need for a safe and effective therapy that can target highly morbific influenza strains such as Avian flu and to have that therapy stockpiled for a pandemic eruption," said Steven C. Quay, M.D., Ph.D., Chief Scientific Officer of MDRNA. "Capitalizing on both our proprietary RNAi technologies and our proprietary drug delivery capabilities, we experience developed an RNAi-based compound that crapper address all strains of influenza A virus by targeting conserved regions of the grippe viral genome. Ongoing and future studies, in quislingism with the U.S. Centers for Disease Control and Prevention, will continue to analyze the intranasal pitch of our Dicer substrate siRNA for influenza and provide us further penetration into the strength of our therapeutical and delivery approaches."
About Influenza
Influenza infects millions of people worldwide and results in hundreds of thousands of deaths every year. The World Health Organization and the U.S. Centers for Disease Control and Prevention are concerned about the potential for a major global pandemic, such as the 1918 "Spanish Flu" in which up to 50 billion people crataegus laevigata have died worldwide. A global pandemic flu emerges from a sudden change in the influenza viral genome resulting in a new viral strain for which in that respect may be no pre-existing immunity or vaccine. Vaccines currently exemplify the mainstay of influenza prevention, merely vaccines get two winder limitations. First, they are developed against individual, known circulating strains of flu and so may not be effectual against new viral strains. Second, vaccines are produced using a lengthy process requiring incubation in gallus gallus eggs. Hence, a vaccine against a new viral strain would not be readily available. Influenza, wish many viruses, has the potential to mutate and become resistant to the very drugs developed to treat flu. The potential advantage of RNAi therapeutics over traditional antiviral drugs is that siRNAs lavatory be developed to target the conserved region of the flu viral genome. This means that an RNAi healing would be expected to be efficacious against all emerging strains of the influenza virus since the "conserved part" very seldom mutates. Therefore, it would be possible to stockpile an effective RNAi-based therapeutic in advance of a global flu pandemic. In addition to their electric potential for treating a pandemic influenza irruption, RNAi therapeutics could besides serve as a treatment for the more unwashed strains responsible for seasonal worker flu that can solvent in hospitalisation and death each year.
About Dicer Substrates and RNA Interference (RNAi)
RNA interference, or RNAi, is a naturally occurring tract inside of cells that can be used to turn sour the production of a specific protein or proteins to treat a wide variety of diseases. Dicer substrates are slightly longer double marooned RNAs than conventional siRNAs and are directed to a step in RNAi process ahead RISC formation that produces a more potent knockdown of the targeted gene. In the case of an RNAi directed against influenza, the targets are proteins critical for viral replication. By turning sour the production of such proteins, the spread of infection is prevented or slowed.
About MDRNA, Inc.
MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). Our goal is to amend human health through the development of RNAi-based compounds and dose delivery technologies that together provide superior therapeutic options for patients. Over the past decennary, we consume developed solid capabilities in molecular biology, cellular biology, lipid chemical science, peptide chemistry, pharmacology and bioinformatics, which we are applying to a wide of the mark range of RNAi technologies and delivery approaches. These capabilities asset the in-licensing of key RNAi-related noetic property make rapidly enabled us to become a leading RNAi-based therapeutics fellowship with a pre-clinical word of mouth in samara therapeutic areas including oncology, metabolic disorders and redness. Through our capabilities, expertness and know-how, we ar incorporating multiple RNAi technologies as well as peptide and lipid-based delivery approaches into a single integrated drug discovery platform that will be the engine for our clinical word of mouth as well as a versatile platform for establishing broad therapeutic partnerships with biotechnology and pharmaceutical companies. We ar also investment in new technologies that we expect to lead to safer and more effective RNAi-based therapeutics patch aggressively building upon our broad and extensive intellectual property estate of the realm. By combining broad expertness in siRNA science with proven manner of speaking platforms and a strong IP status, MDRNA is well positioned as a leading RNAi-based drug discovery and ontogenesis company. Additional information about MDRNA, Inc. is uncommitted at hTTP://www.mdrnainc.com.
MDRNA Forward-Looking Statement
Statements made in this news spillage may be forward-looking statements within the meaning of Federal Securities laws that are topic to sure risks and uncertainties and involve factors that english hawthorn cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but ar not limited to: (i) the ability of MDRNA or a subsidiary to obtain extra funding; (ii) the ability of MDRNA or a subsidiary to attract and/or maintain manufacturing, research, developing and commercialisation partners; (tierce) the ability of MDRNA, a subsidiary and/or a partner to successfully fill in product research and development, including presymptomatic and clinical studies and commercialization; (iv) the ability of MDRNA, a subsidiary and/or a partner to obtain needed governmental rovals; and (v) the ability of MDRNA, a subsidiary and/or a pardner to develop and commercialize products that can contend favorably with those of competitors. Additional factors that could cause actual results to take issue materially from those sticking out or suggested in any forward-looking statements are contained in MDRNA's most recent periodic reports on Form 10-K and Form 10-Q that ar filed with the Securities and Exchange Commission. MDRNA assumes no obligation to update and supplement forward-looking statements because of subsequent events.
MDRNA, Inc.
More information
Wednesday, 20 August 2008
Sunday, 10 August 2008
Clash's Shea Stadium gig captured on disc
1982 performance features many favorites
NEW YORK -- Long bootlegged and sought later by collectors, the Clash's Oct. 13, 1982, performance at New York's Shea Stadium testament finally see official release Oct. 7 via Legacy.
The gig base the Clash opening for the Who on the latter band's "farewell" tour, and features a wealth of favorites, from "London Calling" and "Police on My Back" to "The Magnificent Seven" and "Clampdown."
The band, which was touring in support of its album "Combat Rock," besides offered up the singles from that effort, "Should I Stay or Should I Go" and "Rock the Casbah." According to Legacy, late guitarist Joe Strummer constitute the Shea tapes piece preparing to move into a new house.
In other Clash news, a new biography culled from extensive band interviews, "The Clash by the Clash," will be released Nov. 4 via Grand Central Books.
Here is the track list for "Live at Shea Stadium":
Kosmo Vinyl Introduction
"London Calling"
"Police on My Back"
"Guns of Brixton"
"Tommy Gun"
"The Magnificent Seven"
"Armagideon Time"
"The Magnificent Seven" (return)
"Rock the Casbah"
"Train in Vain"
"Career Opportunities"
"Spanish Bombs"
"Clampdown"
"English Civil War"
"Should I Stay or Should I Go"
"I Fought the Law"
NEW YORK -- Long bootlegged and sought later by collectors, the Clash's Oct. 13, 1982, performance at New York's Shea Stadium testament finally see official release Oct. 7 via Legacy.
The gig base the Clash opening for the Who on the latter band's "farewell" tour, and features a wealth of favorites, from "London Calling" and "Police on My Back" to "The Magnificent Seven" and "Clampdown."
The band, which was touring in support of its album "Combat Rock," besides offered up the singles from that effort, "Should I Stay or Should I Go" and "Rock the Casbah." According to Legacy, late guitarist Joe Strummer constitute the Shea tapes piece preparing to move into a new house.
In other Clash news, a new biography culled from extensive band interviews, "The Clash by the Clash," will be released Nov. 4 via Grand Central Books.
Here is the track list for "Live at Shea Stadium":
Kosmo Vinyl Introduction
"London Calling"
"Police on My Back"
"Guns of Brixton"
"Tommy Gun"
"The Magnificent Seven"
"Armagideon Time"
"The Magnificent Seven" (return)
"Rock the Casbah"
"Train in Vain"
"Career Opportunities"
"Spanish Bombs"
"Clampdown"
"English Civil War"
"Should I Stay or Should I Go"
"I Fought the Law"
Subscribe to:
Posts (Atom)